TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02112851

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Orange flavored beverage
Description: Intervention involves consumption of one beverage of 240ml following baseline measurements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange flavored beverage
Description: Intervention involves consumption of one beverage of 240ml following baseline measurements
Study: NCT03371784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: I.V. administration
Study: NCT02112851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange flavored beverage
Description: Intervention involves consumption of one beverage of 240ml following baseline measurements
Study: NCT03346096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: fixed dose 5mg/kg on days -7-6
Study: NCT01313377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin

Intervention type: OTHER
Group type: OTHER
Intervention: clinical observation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: OTHER
Intervention: quality-of-life assessment
Study: NCT03487562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin 500 mg
Study: NCT03371784

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: I.V. administration
Study: NCT00517361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 6 in 250mL saline IV over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 15mg/kg in 100mL saline IV over 60 - 90 minutes
Study: NCT03631758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence-based information
Description: Evidence-based information on mammography such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence-based information
Description: Evidence-based information on mammography such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid
Description: Patient Decision Aid for breast cancer screening decision

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham information
Description: Educational information not specific to mammography or cancer screening
Study: NCT03549377

Intervention type: BEHAVIORAL
Intervention: Deception
Description: Participants will be deceived during delayed gratification task.
Study: NCT01289678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Famotine 20mg IV push daily just prior to the aldesleukin (IL-2) IL-2 18 million IU/m2 in 50 mL 5% D5 or NS IVPB over 15 - 30 minutes daily for 5 days
Study: NCT03487562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin 1 g
Study: NCT02574182

Intervention type: RADIATION
Intervention: Brain MRI
Description: Brain MRI (Magnetic Resonance Imaging) brain is a painless test that allows to visualize the different brain structures.~Korvit, device made up of 2 shoes which reproduces the feeling to go. The Korvit® system appears possible to analyze the activated cerebral zones and to thus try to better understand the operation of the brain during walk.~The GAITRite is a carpet for recording the walking operating parameters

Intervention type: RADIATION
Intervention: Brain MRI
Description: Brain MRI (Magnetic Resonance Imaging) brain is a painless test that allows to visualize the different brain structures.~Korvit, device made up of 2 shoes which reproduces the feeling to go. The Korvit® system appears possible to analyze the activated cerebral zones and to thus try to better understand the operation of the brain during walk.~The GAITRite is a carpet for recording the walking operating parameters

Intervention type: RADIATION
Intervention: Brain MRI
Description: Brain MRI (Magnetic Resonance Imaging) brain is a painless test that allows to visualize the different brain structures.~Korvit, device made up of 2 shoes which reproduces the feeling to go. The Korvit® system appears possible to analyze the activated cerebral zones and to thus try to better understand the operation of the brain during walk.~The GAITRite is a carpet for recording the walking operating parameters
Study: NCT03487562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin 1 g
Study: NCT03927144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG334
Description: Subcutaneous Injection
Study: NCT04768192

Intervention type: PROCEDURE
Intervention: Physical Rehabilitation without lokomat
Description: Conventional physiotherapy is performed in 10 weekly sessions (45 minutes each) over 4 weeks(total 40 sessions).~Specific exercises are administered to improve gait, balance and functional abilities focusing on:~strengthening the gluteus and quadriceps muscles stretching the hip flexor and hamstrings muscles increasing static balance increasing dynamic balance increasing functional abilities improving ground gait going up and down the stairs.~Physiotherapists can choose from a list of 25 standard exercises, according to some constraints:~1. strengthening exercises had to involve all the lower limb joints (no segmental intervention)~2. during each session, at least 4 out of the 7 categories above had to be delivered~3. the impossibility to perform any of the categories above during any session had to be recorded in the patient's treatment diary.~Physiotherapists of the treatments group discuss patients' diaries during weekly meetings.
Study: NCT03927144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG334
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Prophylactic
Description: SOC Oral Tablet/Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Prophylactic
Description: SOC Oral Tablet/Capsule
Study: NCT02732834

Intervention type: BEHAVIORAL
Intervention: Patient recruitment
Description: 6 of the clinician's patients (3 pre-training, 3 post-training) will be recruited to complete brief surveys assessing clinician communication
Study: NCT04445558

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral nutritional supplementation
Description: Adjunction of oral nutritional supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: intradialytic parenteral nutrition
Description: Adjunction of intradialytic parenteral nutrition
Study: NCT02985632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141
Study: NCT01301872

Intervention type: OTHER
Group type: OTHER
Intervention: check biomarker :RAGE
Description: We will check RAGE for all patients who have ARDS included in our study
Study: NCT01166685

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-eluting stent
Description: Everolimus-eluting stent
Study: NCT04768192

Intervention type: PROCEDURE
Intervention: Physical Rehabilitation with Lokomat
Description: The rehabilitation protocol consists of 20 sessions of robotic training alternated with 20 sessions of conventional physiotherapy (CP). Each treatment is performed in 5 weekly sessions (45 minutes each) over 4 weeks.~Robotic training aimed to recovery/improve walking capacity from the initial Gross Motor Function Classification System (GMFCS) level. It is performed using the Lokomat® (Hocoma AG, Volketswil, Switzerland) gait orthosis. Initial set ups includes 50% body weight unload, gait velocity adjusted on the patient individual capability (1.5 km/h on average) and 100% guidance force. Both weight unload and guidance force are gradually reduced across sessions according to patient recovery of muscle strength and allowing patients to work harden and move more freely.~Children engagement, active participation and motivation were reinforced through frequent encouragement by therapists and performance feedback implemented in the exercise video-games.
Study: NCT01090414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib tablets or capsules administered orally
Study: NCT04575610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: Subjects randomized to the PF-06650833 arm of the study will receive 200 mg IR suspension formulation every 6 hours (via nasogastric \[NG\] tube, orogastric \[OG\] tube, or equivalent) if unable to take tablets by mouth (PO). Subjects for whom concomitant administration of a strong inhibitor of cytochrome P450 (CYP) 3A4 will have the dose of the IR formulation to 200 mg once daily (QD). Subjects who can take tablets PO will receive 400 mg PF-06650833 (2-200 mg tablets) of the MR formulation QD under fasted conditions (preferably at least 4 hours after and 1.5 hours before a meal). No dose adjustment is needed for subjects taking the MR tablet preparation, except if co-administered with ritonavir in which case the dose should be reduced to 200 mg MR QD. All dosing of PF-06650833 will be in addition to current hospital SOC therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets will be administered.
Study: NCT01597310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: single doses at specified time periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Description: multiple doses
Study: NCT00138008

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: endocrine therapy
Description: Drug: endocrine therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Procedure/Surgery: radiotherapy
Study: NCT01288079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Tablet, oral, twice daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Tablet, oral, twice daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Capsule, oral, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, oral, twice daily for 8 weeks
Study: NCT01111318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: 2 tablets BI 10773 25 mg single dose
Study: NCT01295320

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample will be collected at Month 48, Month 60 and Month 72
Study: NCT01166685

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare-metal stent
Description: Bare metal stent
Study: NCT01204021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chih
Description: 12 weeks of weekly classes of Tai Chi Chih
Study: NCT01204021

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Education Control
Description: Weekly meetings, for 2 hours for 12 weeks discussing issues related to stress education.
Study: NCT03747679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 Mg capsules of bosutinib in Water solution
Description: 200 mg (4X50) Capsules in water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosunitib sorbitol
Description: 200 Mg of bosutinib sorbitol solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib Mannitol
Description: Bosutinib mannitol solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosutinib in mannitol low sweet
Description: bosutinib in mannitol solution low sweet
Study: NCT01166685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodegradable Polymer-DES
Description: drug-eluting stent with bioabsorbable polymer
Study: NCT01246947

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tricuspid valve repair
Description: Randomized to receive Tricuspid valve repair using a rigid 3-dimensional annuloplasty ring using standard techniques, during Mitral surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mitral surgery alone
Description: Randomized to Mitral surgery alone
Study: NCT03487562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin 1 g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin 1 g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin 1 g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 30 mg
Study: NCT01439932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: algometer
Description: Pressure algometer (Algometry) - This is an instrument that measures pain threshold (the minimum pressure required to produce pain). The instrument consists of a flat disk size centimeter square attached to pressure transducer and measuring electrodes. The disk is placed vertically on the point of pain and therapist increases the intensity of the pressure until initial pain appears (when sense of pressure becomes sense of pain.) Score is determined by average of three repeated measurements with 30 seconds break between each.~The algometer allows an objective assessment of pain in addition to LEFS score which is a subjective tool. The algometer test was found to be valid and reliable in repeated measurements (interrater, intrarater) by Andrew A. Fischerin 1987 with healthy people \[Andrew 1987\]. In another study high reliability was found for averaging between three repeated tests: ICC = 0.91 (CI 0.82; 0.97 95%). \[Linda et al 2007\]
Study: NCT04646668

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarette and Heat not burn
Description: Current smokers will be randomized to session order and complete a standardized 10-puff bout (5 minutes) followed by a 60-minute ad libitum session with each product (usual brand cigarette, e-cigarette, heat-not-burn).

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarette and Heat not burn
Description: Current smokers will be randomized to session order and complete a standardized 10-puff bout (5 minutes) followed by a 60-minute ad libitum session with each product (usual brand cigarette, e-cigarette, heat-not-burn).
Study: NCT01256424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAL 5% with illumination
Description: Treatment with a singe dose of 2g, HAL 5% ointment followed by photoactivation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAL 1% with illumination
Description: Treatment with a singe dose of 2g, HAL 1% ointment followed by photoactivation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAL 0.2% with illumination
Description: Treatment with a singe dose of 2g, HAL 0.2% ointment followed by photoactivation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ointment without illumination
Description: Treatment with a singe dose of 2g placebo ointment, no photoactivation
Study: NCT01737463

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic snare papillectomy
Description: Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope. A pancreatic duct stent was or was not inserted immediately after the excision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic snare papillectomy
Description: Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope. A pancreatic duct stent was or was not inserted immediately after the excision.
Study: NCT01636102

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza virus vaccine (TIV)
Description: A single 0.5 mL dose of the study vaccine supplied in prefilled syringes and administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
Study: NCT00528125

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: active laser acupuncture
Description: low level laser acupuncture, 830 nm, 30 mW, 0,3 J per acupoint, 2 points per neonate (Hegu and Shen Men). Overall 30 seconds of treatment

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo laser acupuncture
Description: placebo laser acupuncture at two acupoints (Hegu, Shen Men). Overall treatment time 30 seconds.
Study: NCT03747679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosutinib in mannitol high sweet
Description: bosutinib in mannitol high sweet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosutinib taste low flavour
Description: bosutinib solution low flavour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosutinib high flavour
Description: bosutinib solution high flavour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosutinib capsules in applesauce
Description: Bosutinib capsules in applesauce

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib capsules in yogurt
Description: bosutinib capsules in yogurt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosutinib capsules in water
Description: sham comparator, bosutinb in water retest

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib capsules in low sweet
Description: bosutinib capsules in low sweet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosutinib capsules high sweet
Description: Bosutinib capsules high sweet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosutinib capsules low flavour
Description: Bosutinib capsules low flavour
Study: NCT01852565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darapladib
Description: Enteric coated, free base (micronized) white round tablet, 160mg, Oral/repeat dose/10 days (Treatment Period 1), 14 days (Treatment Period 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Extended release, Blue capsule imprinted with cardizem CD and 240mg on one end, 240 mg, Oral/repeat dose/17 days
Study: NCT03301168

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-501 T cells
Description: T cells transduced with CaspaCIDe® safety switch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: administered to inactivate BPX-501 cells in the event of GVHD
Study: NCT04470648

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test for SARS-COV2 serology
Description: each person who will accept to participate will have a bood test for a SARS-COV2 serology
Study: NCT02091856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Cognitive behavioral therapy (CBT) represents a psychotherapeutic approach that helps patients understand the thoughts and feelings that influence behaviors. The underlying concept behind CBT is that thoughts and feelings play a fundamental role in behavior. Beyond the conventional CBT techniques proven effective for MDD, the Positive CBT intervention includes set of exercises devised from the positive psychology paradigm. Similarly, the Christian CBT intervention includes a comparable set of exercises rooted on the general Christian belief.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Cognitive behavioral therapy (CBT) represents a psychotherapeutic approach that helps patients understand the thoughts and feelings that influence behaviors. The underlying concept behind CBT is that thoughts and feelings play a fundamental role in behavior. Beyond the conventional CBT techniques proven effective for MDD, the Positive CBT intervention includes set of exercises devised from the positive psychology paradigm. Similarly, the Christian CBT intervention includes a comparable set of exercises rooted on the general Christian belief.
Study: NCT03541317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 1 Strategy: REP
Description: Schools will receive a daylong didactic training covering core elements of CBT and proper screening and identification of students; training to help SPs identify eligible students; a package that includes tools to deploy CBT; and ongoing technical assistance in CBT implementation.
Study: NCT03190252

Intervention type: OTHER
Intervention: Exposure to oxygen partial pressure of 130 kPa
Description: Open sea diving to a maximum depth of 100 msw while breathing Trimix.
Study: NCT03541317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 1 Strategy: REP + Coaching
Description: Schools will receive a daylong didactic training covering core elements of CBT and proper screening and identification of students; training to help SPs identify eligible students; a package that includes tools to deploy CBT; ongoing technical assistance in CBT implementation; and weekly visits from a CBT expert or Coach, for a minimum of 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 2 Strategy: Augment with Facilitation
Description: In addition to first-line treatment (REP or REP + Coaching), schools will also receive support from a Facilitator who is a member of the study team and has expertise in CBT, implementation methods, and use of EBPs in schools will support SPs in strategic thinking and leadership skills to address organizational barriers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 2 Strategy: No augmentation
Description: Schools will continue to receive their first-line treatment (REP or REP + Coaching); no additional support will be offered.
Study: NCT04555434

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics
Description: * Experimental group Main ingredients: P. pentosaceus KID7, L. lactis CKDB001 or L. helveticus CKDB001 (containing 9 × 10\^9 CFU / day)~* Control group Main ingredient: Crystalline cellulose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: * Experimental group Main ingredients: P. pentosaceus KID7, L. lactis CKDB001 or L. helveticus CKDB001 (containing 9 × 10\^9 CFU / day)~* Control group Main ingredient: Crystalline cellulose
Study: NCT02597829

Intervention type: DRUG
Group type: OTHER
Intervention: Certolizumab Pegol
Description: Subcutaneous Injection
Study: NCT03747679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosutinib capsules high flavour
Description: bosutinib capsules in high flavour
Study: NCT04027751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropisetron
Description: Investigators administrated intravenously Tropisetron 5mg before anesthesia induction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Investigators administrated intravenously 0.9% saline solution as a placebo